Effectiveness of Fingolimod versus Natalizumab as Second-Line Therapy for Relapsing-Remitting Multiple Sclerosis in Spain: Second-Line GATE Study

to related objects

Location: Deutsche Nationalbibliothek Frankfurt am Main

Extent: Online-Ressource

Language: Englisch

Bibliographic citation: Effectiveness of Fingolimod versus Natalizumab as Second-Line Therapy for Relapsing-Remitting Multiple Sclerosis in Spain: Second-Line GATE Study ; volume:83 ; number:1 ; year:2020 ; pages:25-33
European neurology ; 83, Heft 1 (2020), 25-33

Creator: Meca-Lallana, José
Ayuso, Teresa
Martínez-Yelamos, Sergio
Durán, Carmen
Contreras Martín, Yessica
Herrera Navarro, Nicolás
Pérez Sempere, Angel
Álvarez-Cermeño, Jose C.
Millán !1261032489!
Meca-Lallana, Virginia
Romero Sevilla, Raúl
Ricart, Javier

DOI: 10.1159/000505778

URN: urn:nbn:de:101:1-2020052800193651900615

Rights: Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.

Last update: 14.08.2025, 10:50 AM CEST

Data provider

This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.

Show original at data provider

Associated

Meca-Lallana, José
Ayuso, Teresa
Martínez-Yelamos, Sergio
Durán, Carmen
Contreras Martín, Yessica
Herrera Navarro, Nicolás
Pérez Sempere, Angel
Álvarez-Cermeño, Jose C.
Millán !1261032489!
Meca-Lallana, Virginia
Romero Sevilla, Raúl
Ricart, Javier

Other Objects (12)

Second-line Therapien bei malignen biliären Tumoren

Sirolimus as a second-line treatment for Graves’ orbitopathy

Medication beliefs in first-line and second-line treated multiple sclerosis patients

Adverse Drug Reactions with First-Line and Second-Line Drugs in Treatment of Tuberculosis

Frequency and patterns of second-line resistance conferring mutations among MDR-TB isolates resistant to a second-line drug from eSwatini, Somalia and Uganda (2014–2016)

Efficacy of fingolimod is superior to injectable disease modifying therapies in second-line therapy of relapsing remitting multiple sclerosis

Trabectedin as second-line treatment in metastatic myxoid liposarcoma: a case report

Congenital tuberculosis (TB) use of second-line medication and therapeutic drug monitoring

Detection of second-line drug resistance in Mycobacterium tuberculosis using oligonucleotide microarrays

Second-line Drug Resistance Characterization in Mycobacterium tuberculosis by Genotype MTBDRsl Assay

Second-line therapy for Helicobacter pylori eradication causing antibiotic-associated hemorrhagic colitis

Drug-resistant urothelial cancer cell lines display diverse sensitivity profiles to potential second-line therapeutics

Second-line Therapien bei malignen biliären Tumoren

Sirolimus as a second-line treatment for Graves’ orbitopathy

Medication beliefs in first-line and second-line treated multiple sclerosis patients

Adverse Drug Reactions with First-Line and Second-Line Drugs in Treatment of Tuberculosis

Frequency and patterns of second-line resistance conferring mutations among MDR-TB isolates resistant to a second-line drug from eSwatini, Somalia and Uganda (2014–2016)

Efficacy of fingolimod is superior to injectable disease modifying therapies in second-line therapy of relapsing remitting multiple sclerosis

Trabectedin as second-line treatment in metastatic myxoid liposarcoma: a case report

Congenital tuberculosis (TB) use of second-line medication and therapeutic drug monitoring

Detection of second-line drug resistance in Mycobacterium tuberculosis using oligonucleotide microarrays

Second-line Drug Resistance Characterization in Mycobacterium tuberculosis by Genotype MTBDRsl Assay

Second-line therapy for Helicobacter pylori eradication causing antibiotic-associated hemorrhagic colitis

Drug-resistant urothelial cancer cell lines display diverse sensitivity profiles to potential second-line therapeutics

Second-line Therapien bei malignen biliären Tumoren

Sirolimus as a second-line treatment for Graves’ orbitopathy

Medication beliefs in first-line and second-line treated multiple sclerosis patients

Adverse Drug Reactions with First-Line and Second-Line Drugs in Treatment of Tuberculosis

Frequency and patterns of second-line resistance conferring mutations among MDR-TB isolates resistant to a second-line drug from eSwatini, Somalia and Uganda (2014–2016)

Efficacy of fingolimod is superior to injectable disease modifying therapies in second-line therapy of relapsing remitting multiple sclerosis

Trabectedin as second-line treatment in metastatic myxoid liposarcoma: a case report

Congenital tuberculosis (TB) use of second-line medication and therapeutic drug monitoring

Detection of second-line drug resistance in Mycobacterium tuberculosis using oligonucleotide microarrays

Second-line Drug Resistance Characterization in Mycobacterium tuberculosis by Genotype MTBDRsl Assay

Second-line therapy for Helicobacter pylori eradication causing antibiotic-associated hemorrhagic colitis

Drug-resistant urothelial cancer cell lines display diverse sensitivity profiles to potential second-line therapeutics

Cultural heritage institutions wishing to register will find more information here.

Fields marked * need to be filled in.

Username*

Please enter your username

Email*

Please enter your email address

Please do not fill this field

First name

Last name

Password*

Please enter your password

Confirm password*

Please enter the same password

I have read the terms of use and the privacy policy for the collection of personal data and accept them. *

This field is required.

I would like to subscribe to the newsletter of the Deutsche Digitale Bibliothek. See newsletter subscription info.

Account created

Your "My DDB" account has been successfully created. Before you can log in to your account, you must click the confirmation link in the message we just sent to the email address you provided.

Effectiveness of Fingolimod versus Natalizumab as Second-Line Therapy for Relapsing-Remitting Multiple Sclerosis in Spain: Second-Line GATE Study

Object Details

References and Relationships

Contributors, Places and Time

Further information

Data provider

Associated

Other Objects (12)

Second-line Therapien bei malignen biliären Tumoren

Sirolimus as a second-line treatment for Graves’ orbitopathy

Medication beliefs in first-line and second-line treated multiple sclerosis patients

Adverse Drug Reactions with First-Line and Second-Line Drugs in Treatment of Tuberculosis

Frequency and patterns of second-line resistance conferring mutations among MDR-TB isolates resistant to a second-line drug from eSwatini, Somalia and Uganda (2014–2016)

Efficacy of fingolimod is superior to injectable disease modifying therapies in second-line therapy of relapsing remitting multiple sclerosis

Trabectedin as second-line treatment in metastatic myxoid liposarcoma: a case report

Congenital tuberculosis (TB) use of second-line medication and therapeutic drug monitoring

Detection of second-line drug resistance in Mycobacterium tuberculosis using oligonucleotide microarrays

Second-line Drug Resistance Characterization in Mycobacterium tuberculosis by Genotype MTBDRsl Assay

Second-line therapy for Helicobacter pylori eradication causing antibiotic-associated hemorrhagic colitis

Drug-resistant urothelial cancer cell lines display diverse sensitivity profiles to potential second-line therapeutics

Second-line Therapien bei malignen biliären Tumoren

Sirolimus as a second-line treatment for Graves’ orbitopathy

Medication beliefs in first-line and second-line treated multiple sclerosis patients

Adverse Drug Reactions with First-Line and Second-Line Drugs in Treatment of Tuberculosis

Frequency and patterns of second-line resistance conferring mutations among MDR-TB isolates resistant to a second-line drug from eSwatini, Somalia and Uganda (2014–2016)

Efficacy of fingolimod is superior to injectable disease modifying therapies in second-line therapy of relapsing remitting multiple sclerosis

Trabectedin as second-line treatment in metastatic myxoid liposarcoma: a case report

Congenital tuberculosis (TB) use of second-line medication and therapeutic drug monitoring

Detection of second-line drug resistance in Mycobacterium tuberculosis using oligonucleotide microarrays

Second-line Drug Resistance Characterization in Mycobacterium tuberculosis by Genotype MTBDRsl Assay

Second-line therapy for Helicobacter pylori eradication causing antibiotic-associated hemorrhagic colitis

Drug-resistant urothelial cancer cell lines display diverse sensitivity profiles to potential second-line therapeutics

Second-line Therapien bei malignen biliären Tumoren

Sirolimus as a second-line treatment for Graves’ orbitopathy

Medication beliefs in first-line and second-line treated multiple sclerosis patients

Adverse Drug Reactions with First-Line and Second-Line Drugs in Treatment of Tuberculosis

Frequency and patterns of second-line resistance conferring mutations among MDR-TB isolates resistant to a second-line drug from eSwatini, Somalia and Uganda (2014–2016)

Efficacy of fingolimod is superior to injectable disease modifying therapies in second-line therapy of relapsing remitting multiple sclerosis

Trabectedin as second-line treatment in metastatic myxoid liposarcoma: a case report

Congenital tuberculosis (TB) use of second-line medication and therapeutic drug monitoring

Detection of second-line drug resistance in Mycobacterium tuberculosis using oligonucleotide microarrays

Second-line Drug Resistance Characterization in Mycobacterium tuberculosis by Genotype MTBDRsl Assay

Second-line therapy for Helicobacter pylori eradication causing antibiotic-associated hemorrhagic colitis

Drug-resistant urothelial cancer cell lines display diverse sensitivity profiles to potential second-line therapeutics

Related objects

Reset password